用T细胞受体向髓状瘤的根源
Zsofia Foldvari1,2, Margs S Brennan3, Aleksei Titov1,2
1Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Nature reviews. Cancer
|August 21, 2025
概括
通过T细胞受体 (TCR) 改造的T细胞在治疗骨髓性恶性瘤方面具有前景,提供了超越干细胞移植的新方法. 针对白血病干细胞是通过这些新疗法实现治愈的关键.
科学领域:
- 血液学
- 免疫疗法
- 癌症学
背景情况:
- 骨髓性恶性瘤起源于造血干细胞或原生细胞,而全源干细胞移植是主要的治疗方法.
- 目前的治疗方法面临严重副作用和高复发率的挑战,需要新的治疗策略.
- 在B细胞癌症中成功的采用CAR T细胞疗法并未有效地转化为骨髓性恶性瘤.
研究的目的:
- 对血性恶性瘤的TCR工程T细胞进行临床试验数据的审查.
- 评估基于TCR的恶性骨髓瘤治疗的潜力.
- 讨论针对白血病干细胞和推进TCR疗法的策略.
主要方法:
- 对血液恶性瘤中TCR工程T细胞的临床试验数据的审查.
- 分析使骨髓性恶性瘤适合基于TCR的疗法.
- 讨论针对白血病干细胞的新目标识别和策略.
主要成果:
- 通过TCR工程的T细胞提供了CART细胞的替代品,用于瘤中向细胞内抗原.
- 骨髓性恶性瘤具有特征,使其成为基于TCR的治疗的有吸引力的候选人.
- 向耐治疗白血病干细胞对于实现治愈结果至关重要.
结论:
- 通过TCR工程的T细胞代表了神经质恶性瘤的有希望的治疗途径.
- 为了有效治疗白血病干细胞,需要对新的标和TCR进行进一步的研究.
- 标准化临床前测试和数据共享对于TCR疗法的临床进步至关重要.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.5K
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
431
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
